LONDON, March 21, 2017 /PRNewswire/ -- SMi Group'sá4th annual Immunogenicity conference and exhibition promises
The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.
Featured Immunogenicity specialists, academic and regulatory authorities will offer knowledgeable exploration of the regulations surrounding immunogenicity testing from the UK, Europe, and USA, providing exclusive opportunities for debate and discussion with key regulatory influencers. New ways of overcoming immunogenicity and bioassay challenges will also be thoroughly divulged over two days.
Keynote speakers include Oreda Boussadia, European Head of Business Development and Annie de Groot, CEO & CSO of EpiVax Inc, Sophie Tourdot, Scientific Project Manager, INSERM and Vibha Jawa, Director, Biologics and Vacancies Analytics, Merck.
Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.
There is currently a ú300 early bird discount for all bookings made before 31st March 2017. For more information visit www.immuno.co.uk/prlog
4th IMMUNOGENICITY 201712th ľ 13th June 2017London, UKwww.immuno.co.uk/prlog
Follow the conversation on Twitter and LinkedIn at #immuno17
Press release distributed by PRLog
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-focus-unwanted-immunogenicity-of-immune-oncology-drugs-with-mhra-epivax-roche-novartis-abbvie--many-more-300426943.html
SOURCE SMi Group
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All